Relay Therapeutics (RLAY) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free RLAY Stock Alerts $6.64 +0.13 (+2.00%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | globenewswire.comRelay Therapeutics to Host New Program and Platform Event on June 6, 2024May 13, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Lifted to Overweight at BarclaysMay 12, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up to $6.31May 10, 2024 | msn.comRelay Therapeutics upgraded by Barclays ahead of data readoutMay 10, 2024 | msn.comBarclays Upgrades Relay Therapeutics (RLAY)May 10, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Raised to "Overweight" at BarclaysBarclays raised Relay Therapeutics from an "equal weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a report on Friday.May 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst ConfidenceMay 7, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 5.2%Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.2%May 6, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Buy" from AnalystsShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among analMay 4, 2024 | finance.yahoo.comRelay Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings ResultsRelay Therapeutics (NASDAQ:RLAY - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.08. The firm had revenue of $10.01 million during the quarter, compared to analyst estimates of $0.12 million. Relay Therapeutics had a negative return on equity of 42.43% and a negative net margin of 1,263.49%. The firm's quarterly revenue was up 4327.9% on a year-over-year basis. During the same period last year, the company posted ($0.78) EPS.May 3, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up on Earnings BeatRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up After Earnings BeatMay 2, 2024 | finance.yahoo.comRelay Therapeutics Outperforms Revenue Expectations in Q1 2024May 2, 2024 | investorplace.comRLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | globenewswire.comRelay Therapeutics Reports First Quarter 2024 Financial Results and Corporate HighlightsApril 30, 2024 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 SharesApril 29, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $10,814.10 in StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $6.38, for a total value of $10,814.10. Following the completion of the transaction, the chief financial officer now owns 339,803 shares of the company's stock, valued at approximately $2,167,943.14. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.April 26, 2024 | marketbeat.comRelay Therapeutics (RLAY) Scheduled to Post Earnings on ThursdayRelay Therapeutics (NASDAQ:RLAY) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.April 25, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 7.6% Relay Therapeutics (NASDAQ:RLAY) Trading Down 7.6%April 25, 2024 | globenewswire.comRelay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024April 24, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low at $5.74Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year Low at $5.74April 18, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low at $5.95Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low at $5.95April 17, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 4.9%Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9%April 11, 2024 | globenewswire.comRelay Therapeutics to Participate in Upcoming Investor ConferencesApril 11, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by BrokeragesShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and oApril 3, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 3.3%Relay Therapeutics (NASDAQ:RLAY) Trading Down 3.3%March 27, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading Up 6.2%Relay Therapeutics (NASDAQ:RLAY) Shares Up 6.2%March 19, 2024 | markets.businessinsider.comStrong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic DirectionMarch 19, 2024 | marketbeat.comLeerink Partnrs Comments on Relay Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:RLAY)Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Leerink Partnrs issued their Q2 2024 earnings per share estimates for Relay Therapeutics in a research note issued on Sunday, March 17th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.64) per share for tMarch 16, 2024 | finance.yahoo.comRLAY Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comRLAY Apr 2024 7.500 putMarch 15, 2024 | investorplace.com3 Precision Medicine Stocks That Could Benefit From the Industry's RiseMarch 14, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 6.7%Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 6.7%March 13, 2024 | seekingalpha.comRelay Therapeutics: Platform More Important Than ProgramsMarch 6, 2024 | marketbeat.comFmr LLC Lowers Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Fmr LLC cut its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 28.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,107,733 shares of the company's stock after sellingMarch 4, 2024 | marketbeat.comTrexquant Investment LP Has $1.67 Million Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)Trexquant Investment LP boosted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 926.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 198,671 shares of the company's stock after buying an additional 179,317 shares durinFebruary 27, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Algert Global LLCAlgert Global LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 61.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,823 shares of the company's stock after purchasinFebruary 26, 2024 | globenewswire.comRelay Therapeutics to Participate in Three Upcoming Investor ConferencesFebruary 26, 2024 | markets.businessinsider.comRelay Therapeutics: Strong Buy on Improved Financials and Promising Future MilestonesFebruary 25, 2024 | fool.comRelay Therapeutics (NASDAQ: RLAY)February 24, 2024 | finance.yahoo.comRelay Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 23, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Announces Earnings ResultsRelay Therapeutics (NASDAQ:RLAY - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative return on equity of 38.10%. During the same period last year, the company earned ($0.56) earnings per share.February 23, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sees Large Volume Increase on Better-Than-Expected EarningsRelay Therapeutics (NASDAQ:RLAY) Sees Strong Trading Volume After Earnings BeatFebruary 23, 2024 | finanznachrichten.deRelay Therapeutics, Inc.: Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsFebruary 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline FocusFebruary 22, 2024 | finance.yahoo.comRelay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate HighlightsFebruary 22, 2024 | globenewswire.comRelay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsFebruary 21, 2024 | benzinga.comRelay Therapeutics's Earnings: A PreviewFebruary 21, 2024 | investing.comRelay Therapeutics Inc (RLAY)February 21, 2024 | marketbeat.comRafferty Asset Management LLC Lowers Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Rafferty Asset Management LLC cut its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 39.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 377,745 shares of the company's stock after selling 249,268 shares durin Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. RLAY Media Mentions By Week RLAY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.090.42▲Average Medical News Sentiment RLAY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼22▲RLAY Articles Average Week Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MESO News PRME News RGNX News CRGX News HUMA News PROK News IMTX News KYTX News HLVX News AUTL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.